The Fifth Circuit's affirmation of Act 358 is a loss for AZN, but the financial impact is likely modest and already anticipated given similar state laws. Monitor for further state legislation and any potential Supreme Court petition. The ruling does not materially change AZN's near-term outlook given its diversified portfolio and $589B market cap.
AZN drugs
AZN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $193.12entry
- T+1 · 4mo ago −1.99%α −1.68% · $189.28
- T+5 · 4mo ago −14.82%α −15.37% · $164.50
- T+20 · 4mo ago −19.42%α −22.58% · $155.62
- T+60 · 7w ago −16.39%α −18.38% · $161.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Fifth Circuit affirmed Louisiana's Act 358, which prohibits drug manufacturers from restricting 340B discounted drug delivery to contract pharmacies. AstraZeneca lost its challenge on preemption and Contracts Clause grounds. The ruling is a modest regulatory setback, potentially increasing the volume of 340B discounted sales, but the financial impact is unquantified and likely small relative to AZN's $589B market cap.
Court Ruling Details
Key Facts
- Fifth Circuit affirmed summary judgment for Louisiana, rejecting AstraZeneca's preemption and Contracts Clause challenges to Act 358
- Act 358 bars manufacturers from interfering with 340B drug delivery to contract pharmacies
- Ruling aligns with prior Fifth Circuit precedent in AbbVie v. Fitch regarding Mississippi's similar law
- No damages awarded; no financial impact quantified in the ruling
Financial Impact
Unquantified regulatory setback, potential increase in 340B discounted drug volumes through contract pharmacies, but no immediate financial impact stated
Risk Factors
- Further state laws restricting 340B contract pharmacy restrictions
- Potential increased volume of 340B discounted sales reducing revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-5d791a3776-AZN |
Track record
77 reports on AZN
18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers